{"filing":{"accession_number":"0001628280-26-066581","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-10-20","report_date":"2026-10-21","primary_document":"q32026resultsannouncement.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026066581/q32026resultsannouncement.htm"},"events":[{"id":36522,"run_id":33674,"accession_number":"0001628280-26-066581","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a financial update and earnings release for Q3 2026 (quarter ended September 30, 2026). It discloses quarterly revenue of US$245 million (19% growth YoY), Precision Medicine revenue of US$201 million (30% growth), and provides FY 2026 guidance of revenue and other income expected to exceed US$1 billion. The document explicitly states \"Telix Reports Third Quarter 2026 Financial Performance\" and includes detailed revenue breakdowns and operational highlights typical of a quarterly earnings announcement.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40972,"accession_number":"0001628280-26-066581","item_number":"EX-99.1","item_title":"a20261021q32026businessu.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a financial update and earnings release for Q3 2026 (quarter ended September 30, 2026). It discloses quarterly revenue of US$245 million (19% growth YoY), Precision Medicine revenue of US$201 million (30% growth), and provides FY 2026 guidance of revenue and other income expected to exceed US$1 billion. The document explicitly states \"Telix Reports Third Quarter 2026 Financial Performance\" and includes detailed revenue breakdowns and operational highlights typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:04:07.737809+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40972,"accession_number":"0001628280-26-066581","item_number":"EX-99.1","item_title":"a20261021q32026businessu.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a financial update and earnings release for Q3 2026 (quarter ended September 30, 2026). It discloses quarterly revenue of US$245 million (19% growth YoY), Precision Medicine revenue of US$201 million (30% growth), and provides FY 2026 guidance of revenue and other income expected to exceed US$1 billion. The document explicitly states \"Telix Reports Third Quarter 2026 Financial Performance\" and includes detailed revenue breakdowns and operational highlights typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:04:07.737809+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-10-20"}]}